BioMimetic Therapeutics Inc.
Appeals court upholds dismissal in BioMimetic shareholder lawsuit
Pessimistic Wright Medical wins FDA date for Augment
Wright Medical (NSDQ:WMGI) said it’s not optimistic about an FDA dispute resolution panel on its Augment biologic bone graft product, now slated for May, and would quickly move to cut costs at the BioMimetic Therapeutics subsidiary it bought back in 2012.
Wright Medical dives on non-approvable letter for Augment bone graft
Wright Medical (NSDQ:WMGI) shares are down nearly 9% today after the medical device company revealed that the FDA won’t approve its Augment bone graft.
Device tax will “absolutely, directly, negatively influence job growth” | MassDevice.com On Call
MASSDEVICE ON CALL — The 1st payments for the 2.3% medical device tax which took effect this year are due at the end of the month, and the burden of those new fees will "absolutely, directly, negatively influence job growth," BioMimetic Therapeutics founder Sam Lynch told reporters.
Wright Medical’s back on track, eager to close BioMimetic buyout
Orthopedic giant Wright Medical (NSDQ:WMGI) is back on track, CEO Robert Palmisano told an audience at the J.P. Morgan Healthcare conference in San Francisco yesterday.
Wright Medical begins buying up BioMimetic shares
Wright merger sends BioMimetic shares up 70%
Cook Medical lands FDA win for Evolution colonic stent | Regulatory Roundup
Cook Medical touts FDA win for next-gen colonic stent
Cook Medical won FDA clearance for the latest of its Evolution line, the Colonic Controlled-Release stent.
Sorin’s 2011 sales stay flat, profits soar | Earnings Roundup
Sorin Group (BIT:SRN) reported flat sales but strong profit growth for 2011, saying it raised earnings by 48.3% and revealing that the cardiac rhythm management slump has made its way across the pond.
The Italian medical device maker posted net income of €58.0 million (~$75.2 million) on sales of €743.4 million (~$963.4 million) for the year ended Dec. 31, 2011. That compares with profits of €39.1 million (~$50.7 million) on sales of €745.8 million (~$966.5 million) during 2010.
BioMimetic slashes 25% of jobs following FDA delays | MassDevice.com On Call
MASSDEVICE ON CALL — BioMimetic Therapeutics (NSDQ:BMTI) cut 25% of its workers in hopes of saving some cash in focusing on getting FDA pre-market approval for its Augment bone graft.
The federal watchdog agency’s advisory panel recommended approving the treatment in May 2011, after releasing a dim summary of the pre-market approval application that sunk BMTI shares by more than 35%.